0.03
-14.29%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About DiagnaMed Holdings
Its shares trade on Canadian Securities Exchange under the ticker DMED.CN. It has been listed since 8 November 2022.
DiagnaMed Holdings Corp. is a biotechnology company, which engages in the development and commercialization of digital therapeutics for mental health and neurological disorders. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2022-11-08. The firm is developing a platform of software-based prescription digital therapeutic products (PDT Products) for detecting brain age and tremors for neurological disorders. Its PDT products include BrainYear and BrainTremor. BrainYear is an electroencephalogram-based (EEG) machine-learning solution to detect an individual’s brain age for use in clinic and at-home. BrainTremor is a wearable device to detect tremors and brain activity for neurological disorders by EEG. The firm is also conducting research and development of digital therapeutics applications with the intent to commercialize its PDT Products in the United States. The company also outsources its research and development in the United States and Canada.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 8 Nov 2022
Leadership
Pay as last reported
- Mr. Andre TurmelExecutive Chairman of the Board, since 2025
- Mr. John KaragiannidisPresident, Chief Executive Officer
- Mr. Edward LowInterim Chief Financial Officer
- Mr. Fabio ChianelliDirector, since 2021C$180,000
- Mr. Ming JangIndependent DirectorC$18,638
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BrainYear uses EEG machine learning for brain age detection in clinics and at-home settings.
- BrainTremor is a wearable device detecting tremors and brain activity via EEG for neurological disorders.
- DiagnaMed develops PDT products for mental health and neurological disorders in the US market.
Weaknesses
- DiagnaMed outsources R&D in the United States and Canada for its digital therapeutics.
- The company's IPO occurred on 8 November 2022, limiting recent market presence.
- DiagnaMed focuses on mental health and neurological disorders without broader therapeutic applications.
Opportunities
- Expanding digital therapeutics market in the United States for mental health and neurological disorders.
- Growing demand for EEG-based solutions like BrainYear and BrainTremor in healthcare.
- Collaborating with US healthcare providers to commercialize PDT products in the US market.
Threats
- Competition from established digital therapeutics companies in the US market.
- Regulatory challenges for EEG-based digital therapeutics in the United States.
- Dependence on US market for commercialization of PDT products without global expansion.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.